Logo image of CMPX

COMPASS THERAPEUTICS INC (CMPX) Stock Fundamental Analysis

NASDAQ:CMPX - Nasdaq - US20454B1044 - Common Stock

2.61  +0.01 (+0.38%)

Premarket: 2.54 -0.07 (-2.68%)

Fundamental Rating

3

Overall CMPX gets a fundamental rating of 3 out of 10. We evaluated CMPX against 572 industry peers in the Biotechnology industry. CMPX has a great financial health rating, but its profitability evaluates not so good. CMPX has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CMPX had negative earnings in the past year.
In the past year CMPX has reported a negative cash flow from operations.
In the past 5 years CMPX always reported negative net income.
CMPX had a negative operating cash flow in each of the past 5 years.
CMPX Yearly Net Income VS EBIT VS OCF VS FCFCMPX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

CMPX's Return On Assets of -32.02% is fine compared to the rest of the industry. CMPX outperforms 65.13% of its industry peers.
Looking at the Return On Equity, with a value of -34.51%, CMPX is in the better half of the industry, outperforming 76.28% of the companies in the same industry.
Industry RankSector Rank
ROA -32.02%
ROE -34.51%
ROIC N/A
ROA(3y)-33.39%
ROA(5y)-54.26%
ROE(3y)-36.29%
ROE(5y)-98.05%
ROIC(3y)N/A
ROIC(5y)N/A
CMPX Yearly ROA, ROE, ROICCMPX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 -100 -200 -300

1.3 Margins

CMPX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CMPX Yearly Profit, Operating, Gross MarginsCMPX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, CMPX has more shares outstanding
Compared to 5 years ago, CMPX has more shares outstanding
There is no outstanding debt for CMPX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CMPX Yearly Shares OutstandingCMPX Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CMPX Yearly Total Debt VS Total AssetsCMPX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

An Altman-Z score of 16.63 indicates that CMPX is not in any danger for bankruptcy at the moment.
The Altman-Z score of CMPX (16.63) is better than 90.97% of its industry peers.
CMPX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 16.63
ROIC/WACCN/A
WACCN/A
CMPX Yearly LT Debt VS Equity VS FCFCMPX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 31.84 indicates that CMPX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 31.84, CMPX belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
A Quick Ratio of 31.84 indicates that CMPX has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 31.84, CMPX belongs to the best of the industry, outperforming 97.70% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 31.84
Quick Ratio 31.84
CMPX Yearly Current Assets VS Current LiabilitesCMPX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

CMPX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.12%.
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 33.72% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-5.86%
EPS Next 2Y-13.22%
EPS Next 3Y-9.34%
EPS Next 5Y33.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CMPX Yearly Revenue VS EstimatesCMPX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
CMPX Yearly EPS VS EstimatesCMPX Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CMPX. In the last year negative earnings were reported.
Also next year CMPX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CMPX Price Earnings VS Forward Price EarningsCMPX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CMPX Per share dataCMPX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 1

4.3 Compensation for Growth

CMPX's earnings are expected to decrease with -9.34% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-13.22%
EPS Next 3Y-9.34%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CMPX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

COMPASS THERAPEUTICS INC

NASDAQ:CMPX (1/21/2025, 8:00:00 PM)

Premarket: 2.54 -0.07 (-2.68%)

2.61

+0.01 (+0.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners55.77%
Inst Owner Change0.42%
Ins Owners6.38%
Ins Owner Change2.82%
Market Cap359.11M
Analysts85.71
Price Target8.16 (212.64%)
Short Float %2.26%
Short Ratio2.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)13.8%
Min EPS beat(2)-3.2%
Max EPS beat(2)30.79%
EPS beat(4)2
Avg EPS beat(4)10.89%
Min EPS beat(4)-14.56%
Max EPS beat(4)30.79%
EPS beat(8)5
Avg EPS beat(8)15.08%
EPS beat(12)7
Avg EPS beat(12)-2.3%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)5.66%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.66%
EPS NY rev (1m)0%
EPS NY rev (3m)16.32%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.41%
Revenue NY rev (3m)-0.97%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 422.48
P/FCF N/A
P/OCF N/A
P/B 2.59
P/tB 2.59
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.35
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.01
BVpS1.01
TBVpS1.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -32.02%
ROE -34.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.39%
ROA(5y)-54.26%
ROE(3y)-36.29%
ROE(5y)-98.05%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.88%
Cap/Sales 6.35%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 31.84
Quick Ratio 31.84
Altman-Z 16.63
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)120.93%
Cap/Depr(5y)77.91%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%0%
EPS Next Y-5.86%
EPS Next 2Y-13.22%
EPS Next 3Y-9.34%
EPS Next 5Y33.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.43%
EBIT Next 3Y1.95%
EBIT Next 5Y29.24%
FCF growth 1Y-65.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-70.7%
OCF growth 3YN/A
OCF growth 5YN/A